Stocks in play: Algernon Pharmaceuticals Inc.

Announced that it has received a No Objection Letter from Health Canada to proceed with a NP-120 (Ifenprodil) COVID-19 Phase 2b/3 multinational clinical trial. The same study protocol is being prepared for submission to the U.S. FDA and Australian regulatory authorities. “The study is an adaptive pilot to pivotal trial design based on guidance documents from the World Health Organization (WHO) to determine if Ifenprodil can improve clinical symptoms of COVID-19 by reducing the number of COVID-19 diagnosed patients from progressing to mechanical ventilation with intubation and death,” said Dr. Mark William’s, Algernon’s CSO. Algernon Pharmaceuticals Inc. shares AGN:CNX are trading up 11.11 percent at $0.50.

Read:

• Efforts to Legalize Psychedelics is Quickly Picking Up Momentum

• Work from Home Policies Creating Multi-Billion-Dollar Opportunity for Video Conferencing

• Where The Hottest IPO Of 2019 Went Wrong

• Part of This $333.3 Billion Industry Remains Unscathed by the Virus